In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zeneca Group PLC

Division of AstraZeneca PLC

Latest From Zeneca Group PLC

Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm

After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?

Manufacturing Quality

INTERVIEW: Faron Chairman Discusses Bettering Pharma's Reputation And Having No Regrets

Frank Armstrong is an industry veteran with no intention of slowing down. Over his 30-year career, he has held CEO roles with five biotechnology companies and led medical science and innovation at Merck Serono, and was previously executive vice president of product development at Bayer and senior vice president of medical research and communications at Zeneca. He now chairs the Finnish pharma company Faron's board and has high hopes for its drug Traumakine.

Therapy Areas Respiratory

Sweden’s Reference Pricing Proposal: A Five-Year Doomsday Clock For Innovation?

Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.

BioPharmaceutical Europe

Have Problem? Try M&A.

M&A was the universal prescription for the medical industry in 1998 as acquisition dollar volumes hit record levels. For some, the dealmaking further separates the haves and have-nots. For others, it's an addictive drug for coping with chronic insufficiency syndrome. But for nearly everyone who's using it, M&A is the easiest, if not always an effective, answer to the increasingly intractable problem of growth.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Sir David Barnes, CEO
    Kim D Slocum, Dir., Commercial Dev.
    Peter Kolker, Intellectual Property Mgr.
  • Contact Info
  • Zeneca Group PLC
    Phone: (44) 1 71 304 5000
    15 Stanhope Gate
    London, W1Y 6LN